ReviewTherapeutic advances in urology2016
Novel immunotherapeutic approaches to the treatment of urothelial carcinoma.
Review in Therapeutic advances in urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Review
- From plague to the promise: The journey of Bacille Calmette-Guérin.Bladder (San Francisco, Calif.) · 2024Article
- BCG as a Vector for Novel Recombinant Vaccines against Infectious Diseases and Cancers.Vaccines · 2020Article
- Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder.Virchows Archiv : an international journal of pathology · 2020Article
- Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Nature reviews. Urology · 2018Review
- Cytotoxicity anticancer activities of anastrozole against breast, liver hepatocellular, and prostate cancer cells.Saudi medical journal · 2017Article
- New therapies in nonmuscle invasive bladder cancer treatment.Indian journal of urology : IJU : journal of the Urological Society of IndiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has long played a role in urothelial cancers with the use of bacille Calmette Guérin (BCG) being a mainstay in the treatment of nonmuscle invasive bladder cancer. Novel therapeutic approaches have not significantly impacted mortality in this population and so a renaissance in immunotherapy has resulted. This includes recombinant BCG, oncolytic viruses, monoclonal antibodies, vaccines, and adoptive T-cell therapy. Herein, we provide a review of the current state of the art and future therapies regarding immunotherapeutic strategies for urothelial carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.